WO2010141680A3 - Hedgehog pathway antagonists and methods of use - Google Patents

Hedgehog pathway antagonists and methods of use Download PDF

Info

Publication number
WO2010141680A3
WO2010141680A3 PCT/US2010/037200 US2010037200W WO2010141680A3 WO 2010141680 A3 WO2010141680 A3 WO 2010141680A3 US 2010037200 W US2010037200 W US 2010037200W WO 2010141680 A3 WO2010141680 A3 WO 2010141680A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hedgehog pathway
pathway antagonists
pathway
antagonists
Prior art date
Application number
PCT/US2010/037200
Other languages
French (fr)
Other versions
WO2010141680A2 (en
Inventor
James K. Chen
Joel M. Hyman
Cory A. Ocasio
Original Assignee
The Board Of Trustees The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees The Leland Stanford Junior University filed Critical The Board Of Trustees The Leland Stanford Junior University
Publication of WO2010141680A2 publication Critical patent/WO2010141680A2/en
Publication of WO2010141680A3 publication Critical patent/WO2010141680A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides for a compound, pharmaceutical preparations, kits and methods for the inhibition of the Hh pathway and the alleviation of cancer and developmental disorders associated with the Hh pathway.
PCT/US2010/037200 2009-06-03 2010-06-03 Hedgehog pathway antagonists and methods of use WO2010141680A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18358709P 2009-06-03 2009-06-03
US61/183,587 2009-06-03

Publications (2)

Publication Number Publication Date
WO2010141680A2 WO2010141680A2 (en) 2010-12-09
WO2010141680A3 true WO2010141680A3 (en) 2011-03-31

Family

ID=43298500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/037200 WO2010141680A2 (en) 2009-06-03 2010-06-03 Hedgehog pathway antagonists and methods of use

Country Status (1)

Country Link
WO (1) WO2010141680A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102329277B (en) * 2011-10-24 2013-08-07 海南霞迪药业有限公司 Method for preparing Parecoxib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060132615A (en) * 2003-12-15 2006-12-21 니뽄 다바코 산교 가부시키가이샤 Cyclopropane compounds and pharmaceutical use thereof
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060132615A (en) * 2003-12-15 2006-12-21 니뽄 다바코 산교 가부시키가이샤 Cyclopropane compounds and pharmaceutical use thereof
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor

Also Published As

Publication number Publication date
WO2010141680A2 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
WO2012019427A8 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
IL219530A (en) Substituted 4-aminocyclohexane compounds, medications comprising said compounds and their use for the production of medications
IL200603A0 (en) Inhibitors of the hedgehog pathway
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
WO2012158843A3 (en) Kinase inhibitors
ZA201000106B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ZA201000087B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
AU2008339918A1 (en) Medicament for the treatment of cancer of the pancreas
BRPI0816881A2 (en) Compound, pharmaceutical composition, use of a compound, and methods for treating diseases or disorders and for preparing a compound.
EP2506712B8 (en) Morphinan derivatives for the treatment of drug overdose
WO2010091197A3 (en) Tablets for combination therapy
EP2058024A4 (en) Medicine sprayer
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2009015037A3 (en) 5-pyridinone substituted indazoles
ZA201103727B (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
ZA200808754B (en) Tetrahydronaphthaline derivatives, methods for the production and use hereof as anti-inflammatory agents
IL201449A0 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
IL201562A0 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784069

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10784069

Country of ref document: EP

Kind code of ref document: A2